Background: Chronic exposure to nicotine elicits physical dependence in smokers, yet the mechanism and neuroanatomical bases for withdrawal symptoms are unclear. As in humans, rodents undergo physical withdrawal symptoms after cessation from chronic nicotine characterized by increased scratching, head nods, and body shakes. Results: Here we show that induction of physical nicotine withdrawal symptoms activates GABAergic neurons within the interpeduncular nucleus (IPN). Optical activation of IPN GABAergic neurons via light stimulation of channelrhodopsin elicited physical withdrawal symptoms in both nicotine-naive and chronic-nicotine-exposed mice. Dampening excitability of GABAergic neurons during nicotine withdrawal through IPN-selective infusion of an NMDA receptor antagonist or through blockade of IPN neurotransmission from the medial habenula reduced IPN neuronal activation and alleviated withdrawal symptoms. During chronic nicotine exposure, nicotinic acetylcholine receptors containing the b4 subunit were upregulated in somatostatin interneurons clustered in the dorsal region of the IPN. Blockade of these receptors induced withdrawal signs more dramatically in nicotine-dependent compared to nicotine-naive mice and activated nonsomatostatin neurons in the IPN. Conclusions: Together, our data indicate that therapeutic strategies to reduce IPN GABAergic neuron excitability during nicotine withdrawal, for example, by activating nicotinic receptors on somatostatin interneurons, may be beneficial for alleviating withdrawal symptoms and facilitating smoking cessation.
Introduction
Adverse health consequences caused by smoking kills approximately 6 million people annually, making nicotine addiction the primary cause of preventable mortality in the world [1] . Smokers attempting to quit face a variety of withdrawal symptoms that oftentimes drive relapse [2] . As in humans, rodents chronically exposed to nicotine exhibit somatic (physical) and affective withdrawal symptoms [3] . Rodent somatic symptoms include increased scratching, head nods, and body shakes [4, 5] , whereas affective symptoms include anxiety and aversion [6] . The initiation and expression of withdrawal is dependent on neuronal nicotinic acetylcholine receptors (nAChRs) as symptoms can be precipitated by administration of nicotinic receptor antagonists during chronic nicotine exposure [7] . While the neurocircuitry underlying withdrawal remains to be completely elucidated, the habenular-interpeduncular axis has recently been implicated in nicotine intake and aversion [8, 9] . Interestingly, direct infusion of a nonspecific nAChR antagonist, mecamylamine, into the interpeduncular nucleus (IPN) can precipitate somatic withdrawal in nicotine-dependent mice, suggesting that the habenular-interpeduncular axis may be important for the expression of somatic signs of nicotine withdrawal. In addition, knockout mice that do not express nAChR a2, a5, or b4 subunits, which are particularly abundant in the IPN, exhibit fewer somatic symptoms during nicotine withdrawal [10, 11] . However, whether the IPN is activated or inhibited after chronic nicotine cessation or is sufficient to trigger somatic or affective withdrawal symptoms is unknown.
Results

GABAergic Neurons in the IPN Are Activated during Nicotine Withdrawal
To determine the effects of nicotine withdrawal on neurons within the IPN, we treated C57BL/6J mice chronically with nicotine via nicotine-laced drinking water (200 ml/ml) to induce dependence. Control mice received water containing an equivalent concentration of tartaric acid (see the Experimental Procedures and Figure 1A ). To precipitate withdrawal, mice were challenged with mecamylamine (1 mg/kg, intraperitoneal [i.p.]) or saline. Confirming that chronic nicotine exposure was sufficient to induce nicotine dependence, somatic physical withdrawal symptoms including scratching, body shakes, and head nods, as well as total withdrawal symptoms, were significantly increased in nicotine-treated mice after mecamylamine injection compared to nicotine-treated mice that received a saline injection ( Figures 1B and 1C ). In addition, the number of symptoms did not differ between nicotine-naive mice that received mecamylamine or saline injection. Mecamylamine-precipitated withdrawal in nicotine-dependent mice was also anxiogenic as mice undergoing withdrawal buried more marbles in the marble-burying test (MBT) and spent less time in the open arms of the elevated plus maze (EPM) compared to nicotine-naive mice ( Figures 1D and 1E ). Increased anxiety was not an artifact of decreased locomotor activity as total arm entries in the EPM did not significantly differ between groups ( Figure 1F ). To test the hypothesis that neurons within the IPN were activated during nicotine withdrawal, we immunolabeled IPN slices for c-Fos, a molecular marker of neuronal activation [12] , and glutamic acid decarboxylase 2/1 (GAD2/1), a marker of GABAergic neurons as the IPN is a GABAergic neuron-rich brain region (Figure S1A available online) [13] . Interestingly, mecamylamine induced c-Fos expression predominantly in chronic-nicotine-treated animals (Figures 2A and 2B ). Two-way ANOVA revealed a significant effect of chronic treatment (F 1,16 = 53.23, p < 0.001) and drug (F 1,16 = 124.5, p < 0.001) and a significant chronic treatment 3 drug interaction (F 1,16 = 51.70, p < 0.0001). Post hoc analysis indicated that the number of c-Fos-immunoreactive (ir) neurons was significantly increased after mecamylamine injection compared to saline injection in nicotine-dependent (p < 0.001), but not nicotine-naïve, mice.
In addition, the number of c-Fos-ir neurons in nicotine-dependent animals that received mecamylamine was significantly greater than the number of c-Fos-ir neurons in nicotine-naive animals receiving mecamylamine (p < 0.001). Colocalization of c-Fos with GAD expression in mecamylamine-injected nicotine-dependent mice occurred in >80% of neurons (Figure 2A, insets) . Together, these data suggest that mecamylamine-precipitated withdrawal induces activation of primarily GABAergic neurons in the IPN.
To test whether excitability of IPN neurons would increase during spontaneous nicotine withdrawal, we treated mice chronically with nicotine (or control solution) as above. Spontaneous withdrawal was then elicited by replacement of the nicotine drinking solution with water. Twenty-four hours after nicotine cessation, brains were sliced, and whole-cell voltage-clamp recordings were made in IPN neurons to measure spontaneous excitatory postsynaptic currents (sEPSCs; Figures 2C and 2D ). EPSC analysis revealed that in comparison to the control, neurons within the IPN of withdrawn mice had increased sEPSC frequency (t 68.9 = 4.35, p < 0.001), but not amplitude, indicating increased excitatory input elicited by increased release of glutamate in the IPN. GAD expression (both GAD1 and GAD2) could be detected in >70% of neurons as measured by single-neuron RT-PCR ( Figure S1B ).
Optical Activation of GAD2-Expressing IPN Neurons Triggers Somatic Withdrawal Symptoms
To test the hypothesis that activation of GABAergic neurons within the IPN was sufficient to elicit the observed nicotine withdrawal symptoms, we selectively expressed channelrhodopsin with an eYFP tag (ChR2-eYFP) in the IPN of GAD2-Cre mice using AAV2-mediated gene delivery of a plasmid containing ChR2-eYFP in a double inverted open reading frame ( Figure S2A ) [14, 15] . Four to six weeks postinfection, significant eYFP signal was observed in GAD2/1-expressing neurons, indicating proper localization to GABAergic neurons ( Figure S2B ). Light stimulation of ChR2-eYFP-positive neurons in IPN midbrain slices from ChR2-eYFP-infected GAD2-Cre mice elicited robust trains of action potentials, whereas neurons from control animals did not respond to light ( Figure S2C ). These data confirmed that ChR2-eYFP was expressed and functional within the IPN.
For activation of GABAergic neurons in vivo, GAD2-Cre mice were infected with AAV2 ChR2-eYFP or control (AAV2-eGFP) virus and optic cannulas were implanted targeting the IPN in both chronic-nicotine-treated and nicotine-naive GAD2-Cre mice 4-6 weeks postinfection. Blue light (via 473 nM LED) was delivered to the IPN in vivo, and somatic withdrawal symptoms were scored ( Figure 3 ). Ten pulses of light at 50 Hz were delivered every 5 s for 10 min ( Figure 3A ). This light stimulation protocol was used to induce phasic firing of these neurons [16] [17] [18] , a stimulation that is also sufficient to induce c-Fos expression [19] , mimicking what is observed during mecamylamine-precipitated withdrawal. Light delivery into the IPN elicited significant withdrawal-like symptoms in chronic-nicotine-treated, ChR2-eYFP-expressing GAD2-Cre mice, including scratching (p < 0.05), body shakes (p < 0.001), and head nodding (p < 0.001), compared to light delivery in control mice, which elicited few symptoms (Figure 3A) . A similar phenotype was also observed in nicotinenaive animals ( Figure S3 ). To determine whether activation of the same neurons within the IPN also triggered the anxiogenic effects of withdrawal, we stimulated neurons as described above and measured anxiety-like behavior in the EPM and MBT assays ( Figure 3B ). Time spent in the open arms of the EPM, as well as total arm entries, did not differ between ChR2-eYFP-expressing GAD2-Cre mice and control animals during light stimulation. Similarly, the number of marbles buried in the MBT was not significantly different in ChR2-eYFP-expressing GAD2-Cre mice at baseline (without light stimulation) compared to during light stimulation. To measure expression and function of ChR2-eYFP in infected animals, we isolated brains after light stimulation and verified eYFP expression under fluorescence microscopy ( Figure 3C ). In addition, the number of c-Fos-ir IPN neurons in ChR2-eYFP-infected mice was significantly greater after light stimulation compared to controls, indicating neuronal activation by light stimulus (Figures 3C and 3D ; p < 0.001).
Glutamate Release from MHb-IPN Afferents Is Necessary for Somatic Nicotine Withdrawal Signs
We next explored the potential mechanism underlying activation of IPN GABAergic neurons during nicotine withdrawal. To test the hypothesis that increased glutamate release in the IPN during nicotine withdrawal is necessary for the observed increase in neuronal activation, we infused saline or an NMDA receptor antagonist, AP5, prior to infusion of mecamylamine, directly into the IPN of control and chronic-nicotine-dependent mice followed by c-Fos analysis ( Figures 4A and 4B ). Two-way ANOVA indicated a significant effect of chronic treatment (F 1,10 = 52.45, p < 0.0001) and infusion (F 1,10 = 37.43, p < 0.0001) and a significant chronic nicotine 3 infusion interaction (F 1,10 = 12.97, p < 0.01). Post hoc analysis revealed that infusion of mecamylamine into the IPN was sufficient to increase the number of c-Fos-ir neurons in nicotine-dependent mice compared to mecamylamine infusion in nicotine-naive animals (p < 0.001). In addition, preinfusion of AP5 reduced the number of c-Fos-ir neurons elicited by mecamylamine in nicotinedependent but not naive animals (p < 0.001). To test the hypothesis that reducing activation of IPN neurons via an NMDA antagonist could alleviate withdrawal symptoms, we infused saline or AP5 directly into the IPN of nicotine-dependent mice undergoing spontaneous withdrawal ( Figure 4C ). Saline infusion did not affect withdrawal symptoms as symptoms were significantly increased compared to baseline responses (symptoms in nicotine-treated mice prior to cessation). In contrast, AP5 infusion during spontaneous withdrawal significantly decreased individual symptoms, including scratching and body shakes, and the number of total symptoms compared to a saline infusion ( Figure 4C , inset). As we have done previously, guide cannulas were verified to target the IPN in each animal [20] (Figure S4A ). Recent data indicate that cholinergic neuron afferents projecting from the medial habenula (MHb) also synthesize and release glutamate into the IPN [21] . To test the hypothesis that MHb neurons provide the source of glutamate that stimulates IPN neurons during withdrawal, we implanted mice with cannulas targeting the MHb and infused lidocaine to block neurotransmission during spontaneous nicotine withdrawal [8] (Figures 4D and S4B ). Lidocaine infusion significantly blocked both individual and total somatic nicotine withdrawal 
IPN Sst Interneurons Express nAChRs Containing the b4
Subunit that Are Upregulated during Chronic Nicotine Exposure Both nicotine cessation and mecamylamine induce withdrawal symptoms, presumably by decreasing/blocking activity of nAChRs. How might a decrease in activity of excitatory nAChRs lead to neuronal activation? This scenario could occur if nAChRs were prominently expressed in a population of inhibitory interneurons, leading to disinhibition of projection neurons or glutamate release from presynaptic terminals upon reduced nAChR activity. To explore this possibility, we examined nAChR expression and function in IPN somatostatin (Sst) interneurons, a subpopulation of interneurons known to exist in the IPN [22] and shown to modulate glutamate release from presynaptic terminals in other brain regions [23] . We laser dissected Sst-immunopositive and -immunonegative IPN neurons and compared nAChR subunit expression from nicotinedependent and nicotine-naive mice using quantitative RT-PCR ( Figure 5A ). Interestingly, immunolabeling of Sst neurons revealed that they are densely clustered within the very dorsal region of the IPN (Figure 5A, insets) . Expression of a2-a7 and b2-b4 nAChR subunits was detected in both neuronal populations. Expression of b3 and b4 nAChR subunits was significantly upregulated in Sst-immunopositive neurons from chronic-nicotine-treated mice compared to nicotine-naive animals (p < 0.05; Figure 5A , bottom), whereas only the a7 subunit was modestly upregulated in Sst-immunonegative neurons from chronic-nicotine-treated mice ( Figure 5A, top) . To determine whether nAChRs in Sst neurons were functionally upregulated after chronic nicotine exposure, we measured whole-cell currents in response to nicotine in IPN slices from nicotine-treated and nicotine-naive mice. Neurons in the dorsal region of the IPN were targeted based on the observed pattern of Sst immunolabeling. Neuronal identity was confirmed by single-neuronal RT-PCR ( Figure S6A ). This analysis also revealed that Sst neurons predominantly express GAD1, whereas GAD2 expression was detected in only ten out of 43 (w23%) Sst-expressing neurons. Nicotine (10 mM) elicited robust inward currents in IPN Sst neurons that were modestly but significantly larger in slices from chronic-nicotine-treated mice ( Figure 5B ; w80% increase, p < 0.05). To determine whether the nAChR subtype underlying responses to nicotine in Sst IPN neurons contained, in part, the b4 subunit, we measured nicotine-induced currents in the presence of SR16584 (20 mM), an antagonist selective for nAChRs containing the b4 subunit [24] . In nicotine-naive slices, SR16584 exhibited a trend to reduce currents induced by nicotine in Sst neurons (w40% reduction), whereas in slices from nicotine-treated mice, SR16584 significantly and robustly reduced nicotine-elicited currents (w75%, p < 0.01).
Blockade of b4 nAChR Signaling in the IPN Elicits Somatic Nicotine Withdrawal Signs
To determine whether blockade of nAChRs containing the b4 subunit could elicit somatic withdrawal symptoms in mice similar to mecamylamine, we infused SR16584 into the IPN of nicotine-treated and control mice. SR16584 induced withdrawal-like symptoms in nicotine-naive animals compared to saline infusion (predominantly rearing and other symptoms; Figure 5C ). However, SR16584 infusion induced a greater number of individual symptoms (including head nodding and body shaking) and a greater number of total symptoms in chronic-nicotine-treated mice compared to nicotine-naive animals, indicating a role for upregulation of nAChRs containing the b4 subunit in physical withdrawal symptoms ( Figure 5D ). Based on our hypothesis, we would expect that blockade of b4 nAChRs would activate non-Sst neurons within the IPN, triggering somatic withdrawal symptoms. To test this hypothesis, we immunolabeled IPN sections for c-Fos and Sst expression after IPN infusion of SR16584 ( Figure S6B ). We were unable to detect c-Fos in Sst-immunopositive neurons, whereas c-Fos was induced by antagonist in Sst-immunonegative neurons. The number of c-Fos neurons induced by SR16584 infusion was significantly greater in both nicotine-naive and nicotine-treated animals compared to a saline infusion. In addition, the number of c-Fos-immunopositive neurons was significantly greater in chronic-nicotine-treated mice compared to nicotine-naive mice. 
Discussion
Here we show that withdrawal from chronic nicotine treatment activates GABAergic neurons of the IPN. GABAergic neuronal activation during withdrawal is mediated, at least in part, by enhancement of excitatory input as EPSC frequencies, but not amplitudes, were increased in GABAergic neurons from nicotine-withdrawn mice compared to nicotine-naive animals. These data suggest increased glutamate release mediates enhanced activation of IPN GABAergic neurons during nicotine withdrawal. Dampening excitability of IPN GABAergic neurons using an NMDA receptor antagonist reduced neuronal activation and alleviated withdrawal symptoms, suggesting that increased glutamate release into the IPN is necessary for expression of somatic withdrawal symptoms. The IPN receives robust input from cholinergic neurons of the MHb [25] . Recent data indicate that these same inputs also synthesize and release glutamate [21] . Consistent with this idea, blocking neurotransmission of the MHb inhibited activation of the IPN during mecamylamine-precipitated nicotine withdrawal and alleviated withdrawal symptoms. Enhanced excitability of IPN GABAergic neurons is mediated by glutamatergic signaling whether withdrawal is precipitated by a mecamylamine infusion or elicited by nicotine abstinence, suggesting the mechanism is similar between both withdrawal paradigms and likely involves decreased nAChR signaling. Indeed, we identified Sst-immunopositive interneurons within the dorsal region of the IPN that robustly expressed nAChRs. Within this population of interneurons, chronic nicotine upregulated gene expression of b3 and b4 nAChR subunits and yielded more robust nicotine-induced currents that were sensitive to a b4 nAChR antagonist. Interestingly, the b3 and b4 nAChR subunits coassemble in the IPN to form a unique nAChR subtype [26] . IPN infusion of a b4 nAChR antagonist triggered robust withdrawal symptoms in nicotine-treated mice and activated non-Sst IPN neurons, indicating a role for b4 nAChRs in somatic nicotine withdrawal symptoms. These data are in agreement with previous studies on b4 nAChR subunit knockout mice, which fail to express somatic nicotine withdrawal symptoms [11, 27] . To our knowledge, this is the first report of a chronic-nicotine-mediated neuroadaptation in the IPN. Together, our data allow us to provide a mechanistic model underlying expression of somatic nicotine withdrawal symptoms ( Figure 6 ). GABAergic (presumably projection) neurons within the IPN receive glutamatergic input from the MHb. Inhibition of MHb glutamatergic terminals is modulated by Sst interneurons clustered in the dorsal portion of the IPN, consistent with the known effect of Sst interneurons in regulating presynaptic glutamate release [23] . During chronic nicotine exposure, nAChRs containing the b3 and b4 subunits are upregulated in Sst interneurons to help increase drive of Sst interneuron activity and offset (i.e., inhibit) glutamate release from the MHb ( Figure 6A ). During spontaneous withdrawal or mecamylamine-precipitated withdrawal, decreased nAChR signaling reduces Sst interneuron activity, thereby disinhibiting glutamate release from the MHb. The increased glutamate release increases excitability of GABAergic neurons, thereby eliciting somatic nicotine withdrawal symptoms ( Figure 6B ). In this scenario, it is likely that a specific population of GABAergic neurons (i.e., non-Sst GABAergic or projection neurons) receive glutamatergic input from MHb projections, whereas Sst neurons may receive MHb cholinergic input, although additional experiments will be needed to test this hypothesis. In our optogenetic experiments, this mechanism is bypassed: ChR2 is expressed in GAD2-expressing neurons, which are predominantly non-Sst neurons as GAD2 was detected in only a small fraction of Sst neurons. Optical activation of GAD2-expressing IPN neurons directly triggers somatic withdrawal-like symptoms regardless of nicotine exposure, indicating that activation of these neurons is sufficient for expression of somatic withdrawal behaviors ( Figure 6C) .
Interestingly, activation of IPN GAD2-expressing neurons did not induce anxiety, suggesting that other brain regions may mediate affective nicotine withdrawal symptoms. Alternatively, distinct populations of neurons within the IPN may be differentially involved in somatic and affective withdrawal symptoms. Regardless, these data are consistent with previous studies indicating somatic and affective withdrawal behaviors, at least in rats, are dissociable [28] . Future experiments are underway to characterize IPN subregions and neuronal subpopulation in the context of drug withdrawal behaviors.
Together, our data are the first demonstrating direct activation of a brain region eliciting physical withdrawal symptoms. Additional brain regions have been implicated in physical symptoms of nicotine withdrawal, including the MHb (confirmed here) and, most recently, the paraventricular nucleus of the hypothalamus, which also projects to the IPN [10, [29] [30] [31] [32] . Thus, the paraventricular nucleus may also be a part of the neural network underlying nicotine somatic withdrawal symptoms. Additional studies should focus on further mapping this network in an effort to identify neuroanatomical targets to reduce withdrawal symptoms. In summary, our data indicate that withdrawal from chronic nicotine activates GABAergic neurons in the IPN. Activation of these neurons is both necessary and sufficient for the induction of somatic withdrawal symptoms. Reducing activation of these neurons, through stimulating Sst interneuron nAChRs, for example, may represent a potential novel therapeutic strategy to alleviate withdrawal symptoms during smoking cessation.
Experimental Procedures Animals
Male C57BL/6J mice and GAD2-Cre mice (Jackson Laboratory) were used in all experiments. GAD2-Cre mice have been described previously and have been backcrossed to a C57BL/6J background for at least one generation [15] . Animals were kept on a standard 12 hr light/dark cycle with lights on at 7:00 a.m. and off at 7:00 p.m. Behavioral experiments were performed during the light cycle. Independent groups of animals were used for each behavioral experiment unless otherwise noted. Mice were housed four per cage and received food and drinking solution ad libitum. All experiments were conducted in accordance with the guidelines for care and use of laboratory animals provided by the National Research Council [33] , as well as with an approved animal protocol from the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School.
Drugs and Drinking Solution
Nicotine and control drinking solutions were prepared from nicotine hydrogen tartrate or L-tartaric acid (Sigma-Aldrich), which were dissolved in tap water with concentrations of 200 mg/ml and 300 mg/ml, respectively. Saccharin Sodium (Fisher Scientific) was added to each solution to sweeten the taste with a concentration of 3 mg/ml. Mecamylamine hydrochloride (1 mg/kg, i.p.) was dissolved in sterile saline. For intra-IPN drug infusions, mecamylamine (2 mg/ml) and AP5 (2 mg/ml) were dissolved in sterile saline. SR 16584 (2.7 mg/ml) was dissolved in 50% dimethyl sulfoxide. For intramHb drug infusion, lidocaine (10 mg/ml) was dissolved in sterile saline. Nicotine and mecamylamine doses are reported as free base.
Mecamylamine-Precipitated and Spontaneous Nicotine Withdrawal
Mice received chronic nicotine treatment via nicotine in the drinking water (i.e., water and nicotine was received from a single bottle) beginning at age 6 weeks. After 6 weeks of nicotine/control drinking solution and 3 days of habituation to saline i.p. preinjection, mice were injected (i.p) with 1 mg/kg of mecamylamine or saline and were immediately put back into their home cages. Somatic withdrawal signs were observed 2 min later and recorded for 20 min. Typical signs include scratching, body shaking, head nodding, backing, rearing, chewing, which were tabulated once/event. ''Other'' behaviors were defined as grooming, circling, jumping, cage scratching, ptosis, and digging and were scored no more than one event per minute. Ninety minutes postinjection, mice were perfused, and the brains were removed for immunohistochemistry. For spontaneous withdrawal, mice were treated with nicotine or control solution for 6 weeks as above. For induction of spontaneous withdrawal, nicotine solution was replaced with control solution. Withdrawal behaviors were measured 24 hr after nicotine cessation. Similar somatic withdrawal signs were observed in mice receiving a 24 hr/day two-bottle choice test (nicotine and control solution), indicating that withdrawal signs also occurred when nicotine exposure was not ''forced.''
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